Zydus Lifesciences receives approval from USFDA to conduct Phase II(b) clinical trial for Usnoflas
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
Increases speed to market for drug developers working on nucleic acid therapeutics
Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A
ICMR will continue to track trends in HMPV circulation throughout the year
Brings together industry experts to discuss preventive steps to protect pigs from African swine fever and best practises for pig farm management
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
JCI accreditation is recognized globally
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
Subscribe To Our Newsletter & Stay Updated